Clinical Trials Browser

INDUSTRY × Carcinoma, Adenoid Cystic × Gynecologic × Clear all

Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05377996 2025-10-28

A Study of XMT-1660 in Participants With Solid Tumors

Phase 1 Recruiting

319 enrolled

BreastGynecologic

Breast Neoplasms, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Phase 2 Completed

185 enrolled

BreastDermatologicGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Malignant mesenchymal tumor, Adenocarcinoma, Brenner Tumor, Carcinoma, Renal Cell, Chondrosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Hemangiopericytoma, Hemangiosarcoma, Leiomyosarcoma, Leukemia, Mast-Cell, Liposarcoma, Mastocytosis, Melanoma, Mesothelioma, Multiple Myeloma, Pleural Neoplasms, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Thymoma, Hypereosinophilic Syndrome, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Rhabdomyosarcoma, Embryonal, Seminoma, Carcinoma, Ductal, Breast, Neurofibrosarcoma, Primary Myelofibrosis, Small Cell Lung Carcinoma

Clinical Trials

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

A Study of XMT-1660 in Participants With Solid Tumors

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases